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Abstract:  Imatinib mesylate (Gleevec®) is a well-established pharmacologic treatment for all 
phases of chronic myeloid leukemia and for advanced gastrointestinal stromal tumors (GISTs).   
Edema-related side effects are relatively common in imatinib therapy with the periocular skin 
representing one of the most common sites for localized edema. While the adverse effect of 
periorbital edema with imatinib is well documented in the oncology literature, there is limited 
reference to this common reaction in the ophthalmology literature. We report two patients with 
upper eyelid edema associated with imatinib therapy who required surgical intervention to 
ameliorate significant visual field obstruction. We highlight the details of each case including 
the histopathologic findings of excised redundant skin followed by a thorough review of the 
literature on imatinib related periorbital edema.
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Introduction
Imatinib mesylate (Gleevec®) is a well-established pharmacologic treatment for 
all phases of chronic myeloid leukemia (CML) and for advanced gastrointestinal 
stromal tumors (GISTs).1–3 Mechanisms of action include selective inhibition of 
several tyrosine kinases, including the bcr-abl fusion protein in CML and the c-kit 
proto-oncogene in GIST.2,4 The most frequently reported side effects include nausea/
vomiting, musculoskeletal pain, diarrhea, fatigue, rash, and edema. The eyelids and 
periocular skin are one of the most common areas where localized edema may arise, 
but edema may regularly occur elsewhere, including the lower extremities and face. 
Severe generalized fluid retention, pulmonary edema, pericardial effusion, pleural 
effusion, cerebral edema, ascites, or anasarca is rare.5,6 Other serious side effects are 
also relatively uncommon, including Stevens–Johnson syndrome, hemolytic anemia, 
internal hemorrhage, and hepatotoxicity.7,8 Additional rare ocular side effects have 
been reported, including cystoid macular edema, optic disc edema, and macular 
ischemia.9–12
While the adverse effect of periorbital edema with imatinib is well documented 
in the oncology literature, there is limited reference to this common reaction in the 
ophthalmology literature.13–15 The eyelid edema is typically mild, worse in the morn-
ing, and is not an indication for cessation of imatinib therapy.16 In only two previously 
reported cases was the edema severe enough to require surgical intervention.15,16
We report two patients with upper eyelid edema associated with imatinib therapy. 
Both patients required surgical intervention to ameliorate significant visual field obstruc-
tion. With only two previous sources in the literature describing the histopathology of Clinical Ophthalmology 2010:4 428
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imatinib-induced edema,15,16 the histopathology of these 
cases is reviewed, including findings of lymphangiectasia 
not reported previously.
Case report 1
A 64-year-old Caucasian female was referred to our oculo-
plastics service for a recent exacerbation of long-standing 
periorbital swelling. She had been diagnosed with CML 
10 years previously, and developed mild upper eyelid swelling 
immediately following initiation of imatinib treatment several 
years prior to presentation. Four months prior to referral to 
us, the patient’s dose of imatinib was increased from 400 to 
600 mg per day in order to induce remission of accelerated 
CML. Several weeks following the increase in her imatinib 
dose, the patient reported severe periorbital swelling, ocular 
heaviness, frequent bilateral ocular discharge with irritation, 
and occasional morning diplopia lasting several hours that she 
observed to be correlated with her degree of swelling. Two 
weeks before our evaluation, she remitted to the chronic phase 
of CML, and her dose of imatinib was decreased to 500 mg 
per day, with a minor improvement in symptoms.
External examination (Figure 1A) revealed bilateral 
ptosis with a margin-reflex distance (MRD) of 1 mm OD 
and 0.5 mm OS, significantly edematous upper eyelid skin, 
normal levator function of 17 mm OU, no lagophthalmos, 
and angular blepharitis in the left lateral canthus. Visual 
acuity was 20/25 - 2 OD and 20/40 + 2 OS. Pupils, motility, 
slit-lamp, tonometry, and funduscopic examination findings 
were unremarkable.
We prescribed erythromycin ointment for blepharitis and 
advised the patient to follow up in clinic for re-evaluation, 
realizing a potential for greater improvement in symptoms 
following the recent decrease in her imatinib dosage. Upon 
her return to clinic six weeks later, the patient reported little 
relief of visual obstruction or irritation. Goldmann ptosis 
visual fields performed at that time demonstrated significant 
superior visual field obstruction to 10° OD and 17° OS, with 
improvement to 38° OD and 41° OS with manual elevation 
of the upper eyelids.
With the patient’s CML maintained on imatinib therapy 
and little relief of ocular symptoms following dose reduc-
tion, the decision was made to proceed with bilateral upper 
eyelid blepharoplasty. At her one-month post-operative 
appointment, the patient reported a dramatic improvement 
in ocular irritation, ocular discharge, morning diplopia, 
and superior field vision obstruction. Examination showed 
  well-healed incisions and marked improvement in eyelid 
  appearance (Figure 1B). During a telephone interview 
50 months following surgery, the patient reported only mild 
periorbital swelling without visual significance, and she 
continues on imatinib 600 mg daily.
Microscopic examination of the two excised specimens 
of upper eyelid tissue (Figure 2) exhibited edema and chronic 
inflammation, consistent with the histopathology of imatinib-
induced eyelid edema previously reported.15,16 The inflam-
mation bore an apparent affinity for perifollicular regions. 
Lymphangiectasia was also noted.
Case report 2
A 66-year-old Caucasian male was referred to our oculoplas-
tic service for slow progression of chronic eyelid swelling that 
he had first noticed five years previously following initiation 
of imatinib for advanced GIST with metastasis to the liver. 
The patient ultimately sought oculoplastic evaluation because 
he began frequently “bumping his head” as a result of severe 
superior field vision obstruction. The patient denied ocular 
discharge, epiphora, or diplopia. At the time of presentation, 
his imatinib dose was 600 mg per day.
A
B
Figure 1 A External photograph of patient 1 preoperatively, demonstrating signifi-
cant upper eyelid edema bilaterally, associated with imatinib therapy.  B One-month 
postoperative photograph, showing marked improvement in eyelid appearance fol-
lowing blepharoplasty.Clinical Ophthalmology 2010:4 429
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reported no residual periorbital edema and continues on 
imatinib 600 mg daily.
Microscopic examination of the resected eyelid tissue 
showed findings identical to those observed in case report 1.
Discussion
Early Phase I and II trials of imatinib for CML and GIST, 
along with subsequent studies examining the side effects 
of imatinib, report incidence rates of edema in the range of 
39%–74.1% in all patients on the medication.1,2,4,13,17 Results 
specifying edema location report the periocular region as 
the most common site of edema, present in 47.6%–70% 
of patients taking imatinib.2,13,17 The causal role of imatinib 
in periorbital edema is strongly suggested by the high fre-
quency of this side effect and the well-documented resolu-
tion of periorbital edema in 12 patients following cessation 
of the drug as a result of severe myelosuppression.13 When 
rechallenged with equivalent or reduced doses of imatinib 
C
A
B
Figure 2 Histopathology of excised eyelid skin (H&E stain).  A: Low-power view showing diffuse edema in the dermis (magnification, x20).  B: At higher magnification (x200), 
dilated lymphatic channels (lymphangiectasia, double-headed arrows) may be appreciated.  Mixed chronic inflammatory cells (block arrow) are seen, much of the inflammation 
occurring adjacent to hair follicles (arrows).  C: Higher magnification (x600) of the area outlined by the rectangle in B).  
Abbreviation: H&E, hematoxylin & eosin.
On examination, the patient had marked bilateral upper 
eyelid ptosis and edema (Figure 3A). MRD measured 
1.5 mm OD and 2 mm OS, with normal levator functions 
of 17 mm OD and 16 mm OS. With the exception of mild 
cataracts OU, the remainder of the examination was unre-
markable. Goldmann ptosis visual fields exhibited severe 
superior visual field obstruction to -16° OD and -13° 
OS that improved to 32° OD and 33° OS with manual 
elevation.
Considering his requirement to continue imatinib therapy 
and the severity of his visual field obstruction, the patient 
opted to undergo bilateral upper eyelid blepharoplasty with 
ptosis repair. At his one-month postoperative follow-up, the 
patient reported dramatic improvement in vision, periocular 
swelling, and overall ocular comfort. Examination revealed 
well-positioned eyelid margins, no lagophthalmos, and mild 
residual edema of the left upper eyelid (Figure 3B). During a 
telephone interview 52 months following surgery the patient Clinical Ophthalmology 2010:4 430
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after bone marrow recovery, periorbital edema recurred in 
eight of the 12 patients.
Valeyrie et al17 found that the mean dose of imatinib 
among patients suffering fluid retention events (471 ± 
113 mg) was significantly greater than the mean dose among 
patients without edema (395 ± 108 mg). Throughout the lit-
erature, the frequency of edema related to imatinib appears 
to be dose-related. Fraunfelder et al13 reported that 10 of 
11 patients (91%) treated with imatinib doses 400 mg 
developed periorbital edema, compared with only 66 
of 94 patients (70%) treated with doses 400 mg. Our 
patients were both on a dose of 600 mg per day at the time 
of presentation. In a series reported by Fraunfelder,13 the 
onset of periorbital edema occurred at an average of 68 ± 
48 days after initiation of treatment (range 1–444 days), and 
no statistically significant correlation was found between 
dose and time of onset. Although it has been suggested 
that female sex and age 65 years are risk factors for 
fluid retention and may predispose to imatinib-induced 
edema,5 Valeyrie et al17 found no significant associations 
between age, sex, and the incidence of edema attributable 
to imatinib.
Although the mechanism for imatinib-induced periorbital 
edema remains unclear, the most popular theory involves the 
inhibition of platelet-derived growth factor receptor (PDGFR) 
signaling by the drug. PDGFR signaling has been shown to 
increase the interstitial fluid pressure in the dermis of rodents.18 
The inhibition of the PDGFR signaling cascade by imatinib 
in human patients may similarly result in increased capillary 
permeability and extravasation of fluid. Preferred localization 
of edema to the periorbital skin is not likely to be explained 
exclusively by this theory, considering only 29% of patients 
with periorbital edema suffered from concomitant peripheral 
edema.13 It has been suggested that the dense collagenous 
orbital septum and poorly developed lymphatic system of the 
orbit predispose this region to edema.16 However, imaging stud-
ies in patients with imatinib-induced periorbital edema show 
the edema to be predominantly isolated to the preseptal region, 
which would suggest that the absence of orbital lymphatics 
may not be relevant in edema formation. In two previously 
reported cases showing histopathology of imatinib-induced 
eyelid edema, findings included loose dermis along with mild 
acute and chronic inflammation.15,16 In our cases, we found the 
inflammation to have an affinity for hair follicles, and we also 
found lymphangiectasia. Although nonspecific, lymphangiec-
tasia correlates with the edema seen clinically.
Periorbital edema secondary to imatinib is typically mild 
to moderate and can usually be managed conservatively. 
While there is little scientific data to guide physicians, 
severe cases of periorbital edema have been treated by vari-
ous means, including prescribing a low-salt diet, topical 1% 
hydrocortisone, 0.25% topical phenylephrine, or oral diuret-
ics.5,6 Severe periorbital edema is not an indication for cessa-
tion of imatinib. For cases of visually obstructive periorbital 
edema refractory to medical management, surgery remains a 
viable option. In our cases and the previous cases of imatinib-
induced periorbital edema requiring surgery, satisfactory 
outcomes were sustained throughout the follow-up period, 
without recurrence of significant edema despite continuation 
of imatinib therapy.15,16 Follow-up in previously published 
cases requiring surgery was 17 months and six months, while 
our patients reported no significant recurrence of periorbital 
swelling at 50 and 52 months postoperatively.
Because of the risk of relapse, it is currently recommended 
that imatinib therapy be continued indefinitely in patients with 
CML.19 Given that imatinib is used for all phases of CML, as 
well as the growing use of imatinib for GIST and in a variety 
of dermatologic conditions,2,3,7 an increasing prevalence of 
A
B
Figure 3 A External photograph of patient 2 preoperatively, demonstrating significant 
upper eyelid edema bilaterally. B One month postoperative external photograph, 
showing marked improvement in eyelid appearance following blepharoplasty and 
ptosis repair.Clinical Ophthalmology 2010:4
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imatinib-induced periorbital edema may be expected in the 
future. The ophthalmologic community should be cognizant 
of this relatively common side effect.
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